Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Mar;31(3):477–479. doi: 10.1128/aac.31.3.477

Drug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virus.

R F Schinazi
PMCID: PMC174758  PMID: 3579265

Abstract

The purpose of this study was to determine whether acyclovir resistance in mice infected with herpes simplex virus could be overcome by using high doses of acyclovir or vidarabine alone or by using a combination of the two drugs. The results indicate that the mice infected intracerebrally were refractory to acyclovir alone but responded to vidarabine or a combination of vidarabine and acyclovir. These observations have major implications for the clinical management of severe herpetic infections, particularly if attempts are to be made to devise means of circumventing drug resistance.

Full text

PDF
477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry D. W., Nusinoff-Lehrman S., Ellis M. N., Biron K. K., Furman P. A. Viral resistance, clinical experience. Scand J Infect Dis Suppl. 1985;47:155–164. [PubMed] [Google Scholar]
  2. Biron K. K., Noblin J. E., de Miranda P., Elion G. B. Uptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected mice. Antimicrob Agents Chemother. 1982 Jan;21(1):44–50. doi: 10.1128/aac.21.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheng Y. C., Schinazi R. F., Dutschman G. E., Tan R. S., Grill S. P. Virus-induced thymidine kinases as markers for typing herpes simplex viruses and for drug sensitivity assays. J Virol Methods. 1982 Nov;5(3-4):209–217. doi: 10.1016/0166-0934(82)90011-8. [DOI] [PubMed] [Google Scholar]
  4. Dix R. D., McKendall R. R., Baringer J. R. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. Infect Immun. 1983 Apr;40(1):103–112. doi: 10.1128/iai.40.1.103-112.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ellis M. N., Barry D. W. Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1985 Feb;27(2):167–171. doi: 10.1128/aac.27.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Field H. J., Darby G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother. 1980 Feb;17(2):209–216. doi: 10.1128/aac.17.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Field H. J., Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978 Oct;81(2):267–277. doi: 10.1017/s0022172400025109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McLaren C., Chen M. S., Ghazzouli I., Saral R., Burns W. H. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother. 1985 Dec;28(6):740–744. doi: 10.1128/aac.28.6.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nahmias A. J., Dowdle W. R. Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol. 1968;10:110–159. [PubMed] [Google Scholar]
  10. Schinazi R. F., Fox J. J., Watanabe K. A., Nahmias A. J. Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother. 1986 Jan;29(1):77–84. doi: 10.1128/aac.29.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schinazi R. F., Peters J., Sokol M. K., Nahmias A. J. Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrob Agents Chemother. 1983 Jul;24(1):95–103. doi: 10.1128/aac.24.1.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schinazi R. F., Peters J., Williams C. C., Chance D., Nahmias A. J. Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother. 1982 Sep;22(3):499–507. doi: 10.1128/aac.22.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schinazi R. F., del Bene V., Scott R. T., Dudley-Thorpe J. B. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):127–134. doi: 10.1093/jac/18.supplement_b.127. [DOI] [PubMed] [Google Scholar]
  14. Svennerholm B., Vahlne A., Löwhagen G. B., Widell A., Lycke E. Sensitivity of HSV strains isolated before and after treatment with acyclovir. Scand J Infect Dis Suppl. 1985;47:149–154. [PubMed] [Google Scholar]
  15. Tenser R. B. Intracerebral inoculation of newborn and adult mice with thymidine kinase-deficient mutants of herpes simplex virus type 1. J Infect Dis. 1983 May;147(5):956–956. doi: 10.1093/infdis/147.5.956. [DOI] [PubMed] [Google Scholar]
  16. Trousdale M. D., Nesburn A. B., Miller C. A. Assessment of acyclovir on acute ocular infection induced by drug-resistant strains of HSV-1. Invest Ophthalmol Vis Sci. 1981 Feb;20(2):230–235. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES